News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

1st Jul 21

Pharmaxis Sells Bronchitol and Aridol Australian Distribution Rights for A$2m

  • Pharmaxis sells Australian distribution rights for Bronchitol®and Aridol® in Australia, New Zealand and several Asian territories to BTC Health effective July 1st, 2021
  • $2m distributor appointment fee to be paid to Pharmaxis
  • Streamlining  mannitol respiratory business in line with strategy
Read full media release - pdf
29th Jun 21

Pharmaxis Announces First Results in Bone Marrow Cancer Trial

First Dose Level in PXS-5505 Myelofibrosis Study Showing Strong Inhibition of Target Enzymes LOX and LOKL2 in Patients

Dosing Commenced in Second Cohort Following Successful Recruitment

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. In addition to the good tolerability and consistent pharmacokinetic properties previously announced, the inhibition of two target enzymes, LOX and LOXL2, were assessed with Pharmaxis proprietary assays and found to be highly statistically significant.

Read full media release - pdf
10th Jun 21

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

PXS-5505 Multinational Trial in Myelofibrosis Cleared by Safety Committee to Advance to Second Stage of Dose Escalation Study.

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced it has completed dosing the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The study’s safety monitoring committee that advises on the study progress, has given the green light to progress to the second dose level after reviewing factors including the safety and pharmacokinetic properties of PXS-5505 in myelofibrosis patients.

Read full media release - pdf